Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.13 CHF | -1.98% |
|
+0.91% | +18.74% |
14/06 | Sandoz AG Re-Submits the Biosimilar Drug EG12014 (Trastuzumab Biosimilar) 150 Mg Powder BLA to the US FDA | CI |
07/06 | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+18.74% | 15.45B | |
+19.02% | 42.97B | |
+24.56% | 22.16B | |
+20.39% | 14.56B | |
+55.81% | 13.03B | |
-0.05% | 6.79B | |
-11.35% | 6.46B | |
+17.73% | 5.87B | |
-8.87% | 5.73B | |
+6.11% | 4.61B |
- Stock Market
- Equities
- SDZ Stock
- News Sandoz Group AG
- Stifel Initiates Sandoz with Buy Rating